Active, not recruitingPhase 2NCT01864109

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Emily Slotkin, MD
Memorial Sloan Kettering Cancer Center
Intervention
Cyclophosphamide(drug)
Enrollment
83 target
Eligibility
1-40 years · All sexes
Timeline
20132027

Study locations (7)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01864109 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis

← Back to all trials